As part of its second quarter earnings report, Biocryst Pharmaceuticals Inc. said it was adding a 14-day treatment cohort to its phase I study in healthy volunteers of kallikrein inhibitor BCX7353, intended as a next-generation, once-daily hereditary angioedema (HAE) therapy.